Establishment of a mouse model of Netherton syndrome based on CRISPR/Cas9 technology (notice n° 604396)

détails MARC
000 -LEADER
fixed length control field 02267cam a2200301 4500500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250121155257.0
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title fre
042 ## - AUTHENTICATION CODE
Authentication code dc
100 10 - MAIN ENTRY--PERSONAL NAME
Personal name Guo, Jin-Zhu
Relator term author
245 00 - TITLE STATEMENT
Title Establishment of a mouse model of Netherton syndrome based on CRISPR/Cas9 technology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Date of publication, distribution, etc. 2022.<br/>
500 ## - GENERAL NOTE
General note 36
520 ## - SUMMARY, ETC.
Summary, etc. BackgroundNetherton syndrome is a rare but severe autosomal recessive disorder with dominant impaired skin barrier function, caused by mutations in the SPINK5 (serine protease inhibitor Kazal-type 5) gene, which encodes LEKTI (lymphoepithelial Kazal-type-related inhibitor). ObjectivesTo establish a murine model of Netherton syndrome based on CRISPR/Cas9 gene editing technology. Materials & Methods Spink5-sgRNA was designed to target exon 3 of the mouse Spink5 gene. Cas9 mRNA and sgRNA were microinjected into the zygotes of C57BL/6J mice. Spink5 homozygous knockout mice were born from a heterozygous intercross, and the phenotype of these mice was compared with wild-type regarding gross morphology, histopathology and immunofluorescent detection of LEKTI. ResultsFollowing microinjection of zygotes using the CRISPR/Cas9 system, sequencing demonstrated a 22-bp deletion at exon 3 of the mouse Spink5 gene. Histological investigation revealed complete detachment of the stratum corneum from the underlying granular layer and an absence of LEKTI in skin from Spink5 homozygous knockout mice. ConclusionThe 22-bp deleted Spink5 transgenic mouse model demonstrates the clinical phenotype and genotype of human Netherton syndrome, representing a useful tool for future gene correction and skin barrier/inflammation studies.
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element animal model
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element CRISPR/Cas9
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element Netherton syndrome
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element SPINK5
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element LEKTI
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Su, Jing
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Dai, Hui
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Wang, Xiao-Yu
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Wu, Wen-Bo
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Chen, Ting
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Zhang, Jennifer
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Wang, Wen-Hui
Relator term author
786 0# - DATA SOURCE ENTRY
Note European Journal of Dermatology | 32 | 4 | 2022-07-01 | p. 459-463 | 1167-1122
856 41 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://shs.cairn.info/revue-european-journal-of-dermatology-2022-4-page-459?lang=en&redirect-ssocas=7080">https://shs.cairn.info/revue-european-journal-of-dermatology-2022-4-page-459?lang=en&redirect-ssocas=7080</a>

Pas d'exemplaire disponible.

PLUDOC

PLUDOC est la plateforme unique et centralisée de gestion des bibliothèques physiques et numériques de Guinée administré par le CEDUST. Elle est la plus grande base de données de ressources documentaires pour les Étudiants, Enseignants chercheurs et Chercheurs de Guinée.

Adresse

627 919 101/664 919 101

25 boulevard du commerce
Kaloum, Conakry, Guinée

Réseaux sociaux

Powered by Netsen Group @ 2025